EGFR and non-small cell lung carcinoma: Motono et al. examined patients with postoperative recurrence of NSCLC and reported the following findings [25]: the 3-year OS rate after recurrence was 79.3% in the EGFR-TKI group (n = 23), 69.5% in the ICI monotherapy group (n = 31), and 43.7% in the cytotoxic chemotherapy group (n = 10).